[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354467-105":59,"doc-detail-354467-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","electronic-patient-reported-outcome-monitoring-system-for-sarcoma-patients-undergoing-drug-treatment-a-development-and-feasibility-study","Electronic patient-reported outcome monitoring system for sarcoma patients undergoing drug treatment - a development and feasibility study","","Electronic patient-reported outcome monitoring for sarcoma patients undergoing drug treatment is evaluated through a prospective development and feasibility study. A collaboration between clinical physicians and system engineers created an electronic system and supported weekly symptom and quality-of-life tracking during anti-tumor therapy. Across 2021–2023, 23 patients were monitored for 12 weeks to 1 year, showing high weekly response and low missing rates, with efficient item completion and strong agreement versus paper-based reporting.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/electronic-patient-reported-outcome-monitoring-system-for-sarcoma-patients-undergoing-drug-treatment-a-development-and-feasibility-study/354467/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/electronic-patient-reported-outcome-monitoring-system-for-sarcoma-patients-undergoing-drug-treatment-a-development-and-feasibility-study/354467.png","ImageObject",300,407,{"name":92,"@type":93},"Guten tag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the aim of the electronic patient-reported outcome (ePRO) system in this study?","Question",{"text":112,"@type":113},"To develop and assess the feasibility of a novel electronic system for monitoring patient-reported outcomes in sarcoma patients receiving drug treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was patient monitoring conducted during drug therapy?",{"text":117,"@type":113},"Patients completed weekly ePRO assessments for 12 weeks to 1 year during administration of anti-tumor agents.",{"name":119,"@type":110,"acceptedAnswer":120},"What feasibility and compliance outcomes were reported?",{"text":121,"@type":113},"The weekly response rate was 95.7% with a missing rate of 0.12%, and the system showed excellent compliance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354467,1790193969,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","Toki etal. BMC Cancer (2026) 26:834 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16196-8](https://doi.org/10.1186/s12885-026-16196-8)  \nRESEARCH Open Access  \nElectronic patient-reported outcome monitoring system for sarcoma patients undergoing drug treatment: a development and feasibility study  \nShunichi Toki1*, Toshihiko Nishisho1, Natsumi Yamashita2, Kunihiko Numoto3, Shinsuke Sugihara4, Teruki Kidani5, Motohiro Kawasaki6,7, Hideki Nishimura8, Shudai Muramatsu6, Hirofumi Namba6, Hiroki Tanioka9,  \nTaketsugu Fujibuchi5, Natsuko Fukuoka8, Yuki Shiko10, Naruto Taira11 and Koichi Sairyo1  \nAbstract  \nBackground Symptom and quality of life monitoring using electronic patient-reported outcomes has been widely adopted for common cancers. However, there are few such systems and studies for rare cancers such as sarcomasin Japan. We herein report a development and feasibility study of a novel system for monitoring electronic patientreported outcomes.  \nMethods Our study group, which included clinical physicians and system engineers as a collaboration between academia and industry, developed the system and conducted weekly electronic patient-reported outcome monitoring for sarcoma patients during the administration of anti-tumor agents. This prospective study was conducted from 2021 to 2023, with each patient monitored for 12 weeks to 1 year.  \nResults Twenty-three patients were included in this study. The weekly response rate and missing rate of the electronic patient-reported outcome system were 95 . 7% and 0 . 12%, respectively. The median time required to answer the items for Performance Status, EuroQol 5-Dimension 5-Level, and 14 symptoms from the Patient-Reported Outcome-Common Terminology Criteria for Adverse Events was 11 s, 46 s, and 123 s, respectively. In a comparison between electronic and paper-based patient-reported outcomes, the intraclass correlation coefficient of the EuroQol index score was 0.92 (95%CI: 0 .89–0. 94) and the weighted kappa coefficient was >0.6 for items in the weekly evaluations. The items that showed the highest rate of moderate or severe grade (at least once in each case) in the whole cohort were general pain (82 . 6%), fatigue (78 . 3%), decreased appetite (73 . 9%) and pain/discomfort (73 . 9%) . Conclusions The novel electronic patient-reported outcome monitoring system for Japanese sarcoma patients undergoing drug treatment is found to be feasible and showed excellent compliance. For the application of the system in clinical practice, an update to implement an alert function based on a precise predictive model, is warranted.  \n*Correspondence: Shunichi Toki [toki830926@gmail.com](toki830926@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nToki et al. BMC Cancer (2026) 26:834 Page 2 of 10  \nKeywords Sarcoma, Patient-reported outcom","cbCais4pQugJF1vw","https://ap.wps.com/l/cbCais4pQugJF1vw","pdf",2008223,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Clinical context of sarcoma and treatment burden","[{\"question\":\"What was the aim of the electronic patient-reported outcome (ePRO) system in this study?\",\"answer\":\"To develop and assess the feasibility of a novel electronic system for monitoring patient-reported outcomes in sarcoma patients receiving drug treatment.\"},{\"question\":\"How was patient monitoring conducted during drug therapy?\",\"answer\":\"Patients completed weekly ePRO assessments for 12 weeks to 1 year during administration of anti-tumor agents.\"},{\"question\":\"What feasibility and compliance outcomes were reported?\",\"answer\":\"The weekly response rate was 95.7% with a missing rate of 0.12%, and the system showed excellent compliance.\"}]","Electronic patient-reported outcome monitoring system for sarcoma patients undergoing drug treatment - a development and feasibility study | PDF",1790110755,25]